PYRIDOSTIGMINE BROMIDE tablet

Riik: Ameerika Ühendriigid

keel: inglise

Allikas: NLM (National Library of Medicine)

Toimeaine:

Pyridostigmine Bromide (UNII: KVI301NA53) (Pyridostigmine - UNII:19QM69HH21)

Saadav alates:

KAISER FOUNDATION HOSPITALS

INN (Rahvusvaheline Nimetus):

Pyridostigmine Bromide

Koostis:

Pyridostigmine Bromide 60 mg

Retsepti tüüp:

PRESCRIPTION DRUG

Volitamisolek:

Abbreviated New Drug Application

Toote omadused

PYRIDOSTIGMINE BROMIDE- PYRIDOSTIGMINE BROMIDE TABLET
KAISER FOUNDATION HOSPITALS
----------
PYRIDOSTIGMINE BROMIDE TABLETS, USP
60 MG
RX ONLY
DESCRIPTION: Pyridostigmine Bromide Tablet is an orally active
cholinesterase inhibitor.
Chemically, pyridostigmine bromide is 3-hydroxy-1-methylpyridinium
bromide dimethylcarbamate. The
molecular formula of pyridostigmine bromide is C H BrN O and molecular
weight is 261.12. Its
structural formula is:
Each Pyridostigmine Bromide Tablet intended for oral administration
contains 60 mg of Pyridostigmine
Bromide USP. In addition, it also contains the following inactive
ingredients: colloidal silicon dioxide,
anhydrous lactose and stearic acid.
CLINICAL PHARMACOLOGY
Pyridostigmine Bromide Tablets inhibits the destruction of
acetylcholine by cholinesterase and thereby
permits freer transmission of nerve impulses across the neuromuscular
junction. Pyridostigmine is an
analog of neostigmine, but differs from it in certain clinically
significant respects; for example,
pyridostigmine is characterized by a longer duration of action and
fewer gastrointestinal side effects.
INDICATIONS AND USAGE
Pyridostigmine Bromide Tablets are useful in the treatment of
myasthenia gravis.
CONTRAINDICATIONS
Pyridostigmine Bromide Tablets are contraindicated in mechanical
intestinal or urinary obstruction, and
particular caution should be used in its administration to patients
with bronchial asthma. Care should be
observed in the use of atropine for counteracting side effects, as
discussed below.
WARNINGS
Although failure of patients to show clinical improvement may reflect
underdosage, it can also be
indicative of overdosage. As is true of all cholinergic drugs,
overdosage of Pyridostigmine Bromide
Tablets may result in cholinergic crisis, a state characterized by
increasing muscle weakness which,
through involvement of the muscles of respiration, may lead to death.
Myasthenic crisis due to an
increase in the severity of the disease is also accompanied by extreme
muscle weakness, and thus may
be diff